Antisense Therapeutics (ASX:ANP) - MD and CEO, Mark Diamond
MD and CEO, Mark Diamond
Source: Antisense Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Antisense Therapeutics (ANP) has presented new data to support its ATL1102 drug and also filed another patent in Australia
  • The biotechnology company reports testing found a statistically significant modulation in two Duchenne Muscular Dystrophy (DMD) disease modifier proteins
  • The result supports the potential of ATL1102 in ambulant DMD and fibrotic conditions
  • ANP has lodged a provisional patent application to cover the new data and associated drug applications
  • Shares in Antisense Therapeutics are up 5 per cent at 21 cents per share at 11:50 am AEST

Antisense Therapeutics (ANP) has presented new data to support its ATL1102 drug and also filed another patent in Australia.

The biotechnology company presented the data at the International Annual Congress of the World Muscle Society.

It unveiled ATL1102 Phase II Non-ambulant Duchenne Muscular Dystrophy patient plasma protein data, which found statistically significant modulation in two DMD disease modifier proteins.

The company explained that the effects position ATL1102 as an exciting prospect for the treatment of both non-ambulant and ambulant DMD patients as well as in the treatment of other muscle and fibrotic conditions.

Antisense Therapeutics Director of Drug Discovery and Patents George Tachas explained the significance of the results.

“The improvement in two genetically inherited modifiers of loss of ambulation in DMD with ATL1102 treatment over six months is to my knowledge yet to be observed with any marketed drugs or those in-development for boys with DMD,” Dr Tachas said.

Antisense Therapeutics CEO Mark Diamond said the company had lodged a provisional patent application to cover the new data and associated drug applications.

“These positive effects on the above proteins strengthens ATL1102’s profile in the treatment of both non ambulant and ambulant DMD patients while positioning it as an exciting prospective therapeutic approach in other muscle and fibrotic conditions,” Mr Diamond said.

“We are excited about this new data and the emerging opportunities that present to expand our development of ATL1102 in DMD and other disease applications in a strategic manner.”

Shares in Antisense Therapeutics were up 5 per cent at 21 cents per share at 11:50 am AEST.

ANP by the numbers
More From The Market Herald
The Market Herald Video

" Paradigm Biopharmaceuticals (ASX:PAR) activates first UK site for phase three clinical trial

Paradigm Biopharmaceuticals (ASX:PAR) has activated its first trial site in the United Kingdom for a third-phase…
Genetic Technologies (ASX:GTG) - CEO, Simon Morriss

" Genetic Technologies (ASX:GTG) expands EasyDNA into Indian and European markets

Genetic Technologies (ASX:GTG) has embarked on a significant expansion of its recently acquired at-home DNA testing…
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…